Cargando…
The Efficacy and Safety of Rituximab in Patients with Idiopathic Inflammatory Myopathy-Associated Interstitial Lung Disease: Case Series
Idiopathic inflammatory myopathy (IIM)-associated interstitial lung disease (ILD) is often rapidly progressive with a poor prognosis; however, no standard therapeutic regimen has been identified. This study aimed to investigate the efficacy and safety of rituximab in IIM-ILD patients. Five patients...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219281/ https://www.ncbi.nlm.nih.gov/pubmed/37240516 http://dx.doi.org/10.3390/jcm12103406 |
_version_ | 1785048972706971648 |
---|---|
author | Jang, Youngeun Yoon, Hee-Young Kim, Hyun-Sook |
author_facet | Jang, Youngeun Yoon, Hee-Young Kim, Hyun-Sook |
author_sort | Jang, Youngeun |
collection | PubMed |
description | Idiopathic inflammatory myopathy (IIM)-associated interstitial lung disease (ILD) is often rapidly progressive with a poor prognosis; however, no standard therapeutic regimen has been identified. This study aimed to investigate the efficacy and safety of rituximab in IIM-ILD patients. Five patients who had been administered rituximab for IIM-ILD at least once between August 2016 and November 2021 were included. Lung function decline was compared one year before and after rituximab. Disease progression, defined as a greater than 10% relative decline in forced vital capacity (FVC) compared to the baseline, was also compared before and after treatment. Adverse events were recorded for safety analysis. Five IIM-ILD patients received eight cycles. FVC-predicted values significantly decreased from 6 months before rituximab administration to those at the baseline (54.1% predicted (pre-6 months) vs. 48.5% predicted (baseline), p = 0.043); however, the FVC decline stabilized after rituximab. The rate of disease progression before rituximab showed a tendency to decrease after rituximab (75% (before) vs. 12.5% (6 months after, p = 0.059) vs. 14.3% (12 months after, p = 0.102)). Three adverse events developed, but none resulted in death. Rituximab can stabilize lung function decline with tolerable safety in Korean IIM patients with refractory ILD. |
format | Online Article Text |
id | pubmed-10219281 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102192812023-05-27 The Efficacy and Safety of Rituximab in Patients with Idiopathic Inflammatory Myopathy-Associated Interstitial Lung Disease: Case Series Jang, Youngeun Yoon, Hee-Young Kim, Hyun-Sook J Clin Med Article Idiopathic inflammatory myopathy (IIM)-associated interstitial lung disease (ILD) is often rapidly progressive with a poor prognosis; however, no standard therapeutic regimen has been identified. This study aimed to investigate the efficacy and safety of rituximab in IIM-ILD patients. Five patients who had been administered rituximab for IIM-ILD at least once between August 2016 and November 2021 were included. Lung function decline was compared one year before and after rituximab. Disease progression, defined as a greater than 10% relative decline in forced vital capacity (FVC) compared to the baseline, was also compared before and after treatment. Adverse events were recorded for safety analysis. Five IIM-ILD patients received eight cycles. FVC-predicted values significantly decreased from 6 months before rituximab administration to those at the baseline (54.1% predicted (pre-6 months) vs. 48.5% predicted (baseline), p = 0.043); however, the FVC decline stabilized after rituximab. The rate of disease progression before rituximab showed a tendency to decrease after rituximab (75% (before) vs. 12.5% (6 months after, p = 0.059) vs. 14.3% (12 months after, p = 0.102)). Three adverse events developed, but none resulted in death. Rituximab can stabilize lung function decline with tolerable safety in Korean IIM patients with refractory ILD. MDPI 2023-05-11 /pmc/articles/PMC10219281/ /pubmed/37240516 http://dx.doi.org/10.3390/jcm12103406 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Jang, Youngeun Yoon, Hee-Young Kim, Hyun-Sook The Efficacy and Safety of Rituximab in Patients with Idiopathic Inflammatory Myopathy-Associated Interstitial Lung Disease: Case Series |
title | The Efficacy and Safety of Rituximab in Patients with Idiopathic Inflammatory Myopathy-Associated Interstitial Lung Disease: Case Series |
title_full | The Efficacy and Safety of Rituximab in Patients with Idiopathic Inflammatory Myopathy-Associated Interstitial Lung Disease: Case Series |
title_fullStr | The Efficacy and Safety of Rituximab in Patients with Idiopathic Inflammatory Myopathy-Associated Interstitial Lung Disease: Case Series |
title_full_unstemmed | The Efficacy and Safety of Rituximab in Patients with Idiopathic Inflammatory Myopathy-Associated Interstitial Lung Disease: Case Series |
title_short | The Efficacy and Safety of Rituximab in Patients with Idiopathic Inflammatory Myopathy-Associated Interstitial Lung Disease: Case Series |
title_sort | efficacy and safety of rituximab in patients with idiopathic inflammatory myopathy-associated interstitial lung disease: case series |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219281/ https://www.ncbi.nlm.nih.gov/pubmed/37240516 http://dx.doi.org/10.3390/jcm12103406 |
work_keys_str_mv | AT jangyoungeun theefficacyandsafetyofrituximabinpatientswithidiopathicinflammatorymyopathyassociatedinterstitiallungdiseasecaseseries AT yoonheeyoung theefficacyandsafetyofrituximabinpatientswithidiopathicinflammatorymyopathyassociatedinterstitiallungdiseasecaseseries AT kimhyunsook theefficacyandsafetyofrituximabinpatientswithidiopathicinflammatorymyopathyassociatedinterstitiallungdiseasecaseseries AT jangyoungeun efficacyandsafetyofrituximabinpatientswithidiopathicinflammatorymyopathyassociatedinterstitiallungdiseasecaseseries AT yoonheeyoung efficacyandsafetyofrituximabinpatientswithidiopathicinflammatorymyopathyassociatedinterstitiallungdiseasecaseseries AT kimhyunsook efficacyandsafetyofrituximabinpatientswithidiopathicinflammatorymyopathyassociatedinterstitiallungdiseasecaseseries |